In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

There are currently two FDA-approved treatments for Alzheimer's: lecanemab and donanemab, which target amyloid plaque and have been shown to modestly slow cognitive decline, though they do not cure ...

There are currently two FDA approved treatments for Alzheimer's: lecanemab and donanemab, which target amyloid plaque and have been shown to modestly slow cognitive decline, though they do not cure ...

In 2023, the Food and Drug Administration (FDA) approved lecanemab, a new therapy for Alzheimer’s disease. This approval brought hope to many patients and doctors since lecanemab is the first ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic ...

The analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab. HealthDay News — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory ...

Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed.

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of ...

THURSDAY, May 15, 2025 (HealthDay News) — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant adverse events is similar to clinical ...

Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (Aug. 1, 2023, to Oct. 1, 2024). The researchers found that infusion-related reactions occurred in 37 ...

Serious side effects of lecanemab can be safely managed, researchers say No patients died of brain swelling and bleeding due to lecanemab Only 4% of patients needed to quit lecanemab due to brain ...